Tirzepatide treatment resulted in 26% body weight reduction in premenopausal women compared to 2% with placebo.
Significant body weight reductions were observed across all reproductive stages with tirzepatide: 26% in premenopause, 23% in perimenopause, and 23% in postmenopause.
Waist circumference reductions were also significant with tirzepatide, showing decreases of 22 cm in premenopause, 20 cm in perimenopause, and 20 cm in postmenopause.
97% to 98% of participants on tirzepatide achieved at least a 5% reduction in body weight, compared to only 29% to 33% with placebo.
30% to 52% of women with baseline BMI < 35 kg/m² reached a waist-to-height ratio of ≤0.49, indicating low central adiposity, with tirzepatide.
Similar outcomes were reported in the additional SURMOUNT-3 and -4 studies.
Simplified
OBJECTIVE: Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage.
METHODS: Women participants from SURMOUNT-1, -3, and -4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre-, peri-, or post-menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight-reduction thresholds, and waist to height ratio () category shift among those with baseline BMI < 35 kg/mwere assessed at end of study treatment. 2
RESULTS: In SURMOUNT-1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/mreached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT-3 and -4. 2
CONCLUSIONS: In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.
Key numbers
24% to 26%
Weight Reduction Increase
Weight loss percentage with vs. placebo in SURMOUNT-1.
20 to 22 cm
Reduction
Reduction in with vs. placebo.
97% to 98%
Achieved Weight Loss Threshold
Proportion of participants achieving ≥5% weight loss with vs. placebo.
Full Text
We can’t show the full text here under this license.
Beverly G. Tchang reports receiving consulting fees as an advisor for Novo Nordisk, Skye Bioscience, and Roman Health Ventures. Andreea Ciudin Mihai reports honoraria from AstraZeneca plc, Boehringer Ingelheim, Eli Lilly and Company, Esteve, and Novo Nordisk A/S for scientific talks, advisory board sessions, and attendance to congresses and is a member of the data monitoring committee for Boehringer Ingelheim clinical trials in obesity. Luis‐Emilio García‐Pérez, Adam Stefanski, Donna Mojdami, Irina Jouravskaya, Sirel Gurbuz, Rebecca Taylor, Chrisanthi A. Karanikas, and Julia P. Dunn are employees and shareholders of Eli Lilly and Company.
